Will Exact Sciences stock go up?
Stock Price Forecast The 17 analysts offering 12-month price forecasts for Exact Sciences Corp have a median target of 95.00, with a high estimate of 160.00 and a low estimate of 50.00. The median estimate represents a +154.90% increase from the last price of 37.27.
Is Exact Sciences a good stock to buy?
Out of 8 analysts, 2 (25%) are recommending EXAS as a Strong Buy, 3 (37.5%) are recommending EXAS as a Buy, 3 (37.5%) are recommending EXAS as a Hold, 0 (0%) are recommending EXAS as a Sell, and 0 (0%) are recommending EXAS as a Strong Sell. What is EXAS's earnings growth forecast for 2022-2024?
Who is the parent company of cologuard?
Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Is exact science profitable?
It posted a net loss of $596 million in 2021, or a net loss of $3.48 per share, compared with a net loss of $824 million, or a loss of $5.45 per share, in 2020.
Is EXAS overvalued?
Exact Sciences Corporation - Hold Valuation metrics show that Exact Sciences Corporation may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of EXAS, demonstrate its potential to underperform the market.
Is Exact Sciences a good company to work for?
Exact Sciences is #7 on Great Place to Work and Fortune's list of the 2020 Best Workplaces in Health Care & Biopharma. The ranking is based on survey responses reflecting the nearly 800,000 employees working at Great Place to Work-Certified organizations in the Health Care & Biopharma industry.
What do gastroenterologists think of Cologuard?
I feel most gastroenterologists would agree Cologuard is a potent weapon in the armamentarium against colon cancer. The 92 percent sensitivity for CRC, and 69 percent sensitivity for detection adenomas with high grade dysplasia, make it the standard second line option, next to colonoscopy.
Does Pfizer own Cologuard?
Pfizer quit on Cologuard a while ago In 2018, when Exact Sciences hired Pfizer to co-promote Cologuard, Pfizer was a very different company. Shortly after signing the agreement with Exact Sciences, Pfizer's former CEO Ian Read handed the leadership role to Albert Bourla.
Will Pfizer buy Exact Sciences?
Exact Sciences Corporation (NASDAQ:EXAS) says that Pfizer (NYSE:PFE) will no longer join the company from Nov.